CymaBay Therapeutics, Inc.
CBAY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CBAY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2023.
Tracking 1 pipeline candidate for CymaBay Therapeutics, Inc..
Run CymaBay Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CymaBay Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
42.5 months
D/E 0.49
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is CymaBay Therapeutics, Inc.'s lead drug candidate?
CymaBay Therapeutics, Inc.'s most advanced tracked candidate is seladelpar (Phase 2) for Nonalcoholic Steatohepatitis (NASH).
Who is the CEO of CymaBay Therapeutics, Inc.?
Janet Dorling is the chief executive officer of CymaBay Therapeutics, Inc. (CBAY).
What therapeutic areas does CymaBay Therapeutics, Inc. focus on?
CymaBay Therapeutics, Inc. develops therapies across Infectious Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.